v3.26.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Jul. 31, 2026
Jul. 31, 2025
Oct. 31, 2025
Segment Reporting [Line Items]          
Revenues  
Research and development expenses 1,326 1,055 3,686 3,929  
General and administrative expenses 1,411 1,381 4,414 4,896  
Total operating expenses 2,737 2,436 8,100 8,825  
Loss from operations (2,737) (2,436) (8,100) (8,825)  
Interest income 112 156 354 519  
Net loss (2,625) (2,280) (7,746) (8,306)  
Total operating expenses 2,737 2,436 8,100 8,825  
Less non-cash stock-based compensation (666) (855) (2,127) (2,899)  
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure) 2,071 1,581 5,973 5,926  
Total assets 15,074   15,074   $ 16,080
Cancer Vaccines [Member]          
Segment Reporting [Line Items]          
Revenues  
Research and development expenses 921 615 2,406 2,489  
General and administrative expenses 960 770 2,847 3,031  
Total operating expenses 1,881 1,385 5,253 5,520  
Loss from operations (1,881) (1,385) (5,253) (5,520)  
Interest income 78 87 231 325  
Net loss (1,803) (1,298) (5,022) (5,195)  
Total operating expenses 1,881 1,385 5,253 5,520  
Less non-cash stock-based compensation (436) (501) (1,344) (1,806)  
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure) 1,445 884 3,909 3,714  
Total assets 10,473   10,473   9,604
CAR-T Therapeutics [Member]          
Segment Reporting [Line Items]          
Revenues  
Research and development expenses 405 440 1,280 1,440  
General and administrative expenses 438 601 1,539 1,825  
Total operating expenses 843 1,041 2,819 3,265  
Loss from operations (843) (1,041) (2,819) (3,265)  
Interest income 33 68 122 191  
Net loss (810) (973) (2,697) (3,074)  
Total operating expenses 843 1,041 2,819 3,265  
Less non-cash stock-based compensation (228) (352) (779) (1,086)  
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure) 615 689 2,040 2,179  
Total assets 4,486   4,486   6,347
Other [Member]          
Segment Reporting [Line Items]          
Revenues  
Research and development expenses  
General and administrative expenses 13 10 28 40  
Total operating expenses 13 10 28 40  
Loss from operations (13) (10) (28) (40)  
Interest income 1 1 1 3  
Net loss (12) (9) (27) (37)  
Total operating expenses 13 10 28 40  
Less non-cash stock-based compensation (2) (2) (4) (7)  
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure) 11 $ 8 24 $ 33  
Total assets $ 115   $ 115   $ 129